The Testosterone Crisis: More Than Just Aging
Testosterone is the primary male androgen governing muscle mass, bone density, cognitive function, mood, and metabolic health. The Massachusetts Male Aging Study documented a decline of 1.6% per year in total testosterone after age 40. More concerning, Travison et al. (JCEM, 2007) identified a population-level decline: men in the 2000s had 15-20% lower testosterone than same-age men in the 1980s, independent of aging.
In the HIM study, 38.7% of men over 45 seen in primary care had low total testosterone (below 300 ng/dL) (Mulligan et al., International Journal of Clinical Practice, 2006) [PMID 16846397]. That is the share of low lab values, not of hypogonadism: clinically significant deficiency — symptoms plus consistently low testosterone — is far less common (Endocrine Society, 2018). Symptoms are nonspecific — fatigue, decreased libido, depression, visceral obesity, brain fog — and frequently misattributed to normal aging or stress.
Total vs Free Testosterone: Why One Lab Is Not Enough
Approximately 98% of circulating testosterone is protein-bound: 60-70% to sex hormone-binding globulin (SHBG) and 25-35% to albumin. Only 1-3% circulates freely. Biological effects depend primarily on free and bioavailable (albumin-bound + free) testosterone.
SHBG increases with age, hyperthyroidism, liver disease, and certain medications. A man with total testosterone of 450 ng/dL but elevated SHBG may have clinically low free testosterone and significant symptoms.
Essential diagnostic panel:
- Total testosterone (morning, fasting, measured twice)
- Free testosterone (calculated or equilibrium dialysis)
- SHBG
- LH, FSH (to differentiate primary vs secondary hypogonadism)
- Estradiol — if breasts are enlarged or tender
- Prolactin
- PSA (prostate-specific antigen)
- CBC (hemoglobin, hematocrit)
- As indicated: lipid panel, HbA1c
Primary vs Secondary Hypogonadism
Primary hypogonadism — testicular failure: elevated LH/FSH with low testosterone. Causes include Klinefelter syndrome, orchitis, trauma, varicocele, cryptorchidism, and chemotherapy.
Secondary (central) hypogonadism — hypothalamic or pituitary dysfunction: low or normal LH/FSH with low testosterone. Causes include obesity, chronic stress, obstructive sleep apnea, opioids, pituitary adenoma, and hyperprolactinemia.
In obese men with insulin resistance, functional secondary hypogonadism is common. Weight loss raises testosterone in proportion to the weight lost, and in some men this avoids TRT (meta-analysis, Corona et al., European Journal of Endocrinology, 2013) [PMID 23482592].
TRT Formulations: Injections, Gels, and Pellets
Intramuscular Injections (Testosterone Cypionate/Enanthate)
The most studied and cost-effective option. Standard dosing: 100-200 mg every 1-2 weeks. Drawback: peak-trough fluctuations ("roller coaster" effect). Subcutaneous micro-injections every 3-4 days (50-80 mg) provide more stable levels and are increasingly preferred.
Transdermal Gels (AndroGel, Testogel)
Daily application to shoulders, abdomen, or inner thighs. Provide stable 24-hour levels. Concerns: skin-to-skin transfer risk to partners and children; absorption variability up to 30% between patients.
Subcutaneous Pellets (Testopel)
Implanted every 3-6 months under buttock skin. Most stable hormone delivery without daily procedures. Handelsman et al. (Clinical Endocrinology, 2017) reported 85-90% patient satisfaction. Drawback: invasive insertion, inability to rapidly discontinue if side effects arise.
DHEA (Dehydroepiandrosterone)
An adrenal prohormone converted to testosterone and estrogens. A meta-analysis in JCEM (2005) showed modest free testosterone increases in men over 60. DHEA is not part of the Endocrine Society (2018) or AUA (2018) recommendations for treating testosterone deficiency — neither as a TRT substitute nor for borderline values.
Safety Monitoring on TRT
Per Endocrine Society (Bhasin et al., JCEM, 2018) and AUA (2018) guidelines:
| Marker | Target / stop |
|---|---|
| Testosterone | mid-normal range (AUA: 450–600 ng/dL) |
| Hematocrit | stop if >54% |
| PSA | rise >1.4 ng/mL in year 1 — urology referral |
| Estradiol | 20–40 pg/mL |
Every 3-6 months:
- Total and free testosterone (target: mid-normal range; AUA: 450-600 ng/dL)
- Hematocrit (stop TRT if >54%: thrombosis risk)
- PSA (urology referral if rise >1.4 ng/mL within the first 12 months)
- Estradiol (target: 20-40 pg/mL; if elevated — review dose and formulation; aromatase inhibitor only for narrow indications, see below)
Annually:
- Lipid panel
- Bone densitometry (if osteopenia present)
- Mood and quality-of-life assessment (ADAM or AMS questionnaire)
Natural Testosterone Optimization
Before initiating TRT, modifiable factors must be addressed:
Sleep. A meta-analysis in Sleep Medicine Reviews (2019): restricting sleep to 5 hours reduces testosterone by 10-15%. Optimal: 7-9 hours of uninterrupted sleep.
Zinc. Zinc supplements are justified when deficiency is documented; a rise in testosterone in men with normal zinc has not been shown. Long-term intake above 40 mg/day exceeds the adult tolerable upper intake level. The Endocrine Society and AUA guidelines do not include zinc as a treatment.
Vitamin D3. Pilz et al. (Hormone and Metabolic Research, 2011) RCT: 3,332 IU daily for one year raised total testosterone from 10.7 to 13.4 nmol/L in vitamin D–deficient men. Later RCTs in men without marked deficiency found no effect on testosterone (Lerchbaum et al., 2017 and 2019) [PMID 28938446] [PMID 30460609]. Correct a vitamin D deficiency; do not take it for testosterone.
Resistance Training. Exercise produces a short-lived rise in testosterone in the hours after a session; a sustained rise in baseline levels or treatment of deficiency has not been shown. Training matters for muscle, bone, and weight loss. Prioritize compound multi-joint movements.
Stress Management. Chronic stress raises cortisol, which suppresses GnRH and testosterone. Data on ashwagandha and testosterone come from small, short studies; the Endocrine Society and AUA guidelines do not include it.
Frequently Asked Questions
Does TRT cause prostate cancer?
A meta-analysis in Medicine (Boyle et al., 2016) and Morgentaler (JAMA, 2023) found no increased prostate cancer risk in men without pre-existing malignancy. TRT is contraindicated in untreated prostate cancer.
Does TRT affect fertility?
Yes. Exogenous testosterone suppresses FSH/LH, which lowers sperm production, up to complete absence of sperm (azoospermia). Guidelines advise against TRT in men planning conception in the near term. If fatherhood is planned, clomiphene or hCG are alternatives.
At what age should testosterone be checked?
With symptoms — at any age. The Endocrine Society (2018) recommends against screening men without symptoms: test when there are symptoms and signs of deficiency — low libido, fewer morning erections, smaller testes, fractures from minor trauma.
Can low testosterone be managed without TRT?
The lower limit of normal total testosterone is 264 ng/dL (9.2 nmol/L) per the Endocrine Society (2018) or 300 ng/dL per the AUA (2018). The diagnosis requires symptoms plus two low morning values, not a single number. If a reversible cause is found — obesity, sleep apnea, opioids, glucocorticoids — treat it first; decide on TRT together with your physician.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.
Erythrocytosis on TRT: Mechanism, Monitoring, and Management
Erythrocytosis is the most common dose-limiting adverse effect, occurring in 11–25% of treated men depending on formulation, with the highest rates in intramuscular regimens producing supraphysiologic peaks. Testosterone stimulates erythropoiesis through three mechanisms: direct suppression of hepcidin (increasing iron availability), stimulation of erythropoietin production by the renal interstitium, and a downward reset of the EPO-hemoglobin set point. The result is a dose-dependent rise in hemoglobin and hematocrit, typically peaking at 3–9 months.
The Endocrine Society 2018 clinical practice guideline recommends discontinuation or dose reduction when hematocrit exceeds 54%. The 54% threshold derives from observational data linking polycythemia vera to thrombotic events; the absolute thrombotic risk in TRT-induced erythrocytosis at 52–54% is less well characterized but the cautionary threshold is retained.
Practical management algorithm: at hematocrit 52–54%, reduce dose by 25–50%, extend injection interval, or switch from intramuscular to transdermal preparation (gels produce hematocrit elevations 2–3 percentage points lower on average). At hematocrit above 54%, hold therapy until hematocrit returns below 50%, then resume at reduced dose. Therapeutic phlebotomy of 450–500 mL removes approximately 200 mg of iron and lowers hematocrit by 3 percentage points; it is appropriate as a bridge but should not be used to permit ongoing supraphysiologic dosing. Coordinate with a blood bank for autologous donation when possible.
Risk modifiers include smoking, obstructive sleep apnea, chronic obstructive pulmonary disease, and high altitude residence, each of which independently raises baseline hematocrit. Obstructive sleep apnea screening (STOP-BANG, polysomnography if indicated) is warranted before initiation in men with elevated BMI or daytime somnolence, as untreated OSA both predisposes to erythrocytosis and is itself worsened by testosterone in a subset of patients. Hydration status should be confirmed before any borderline hematocrit reading is acted upon, and ferritin should be checked annually in men receiving repeated phlebotomy to avoid iatrogenic iron deficiency, which can paradoxically worsen fatigue and obscure the symptomatic benefit of therapy.
Estradiol Management and the Aromatase Inhibitor Question
Approximately 0.2–0.3% of circulating testosterone is converted to estradiol by aromatase, principally in adipose tissue, brain, and bone. Estradiol mediates several physiologic effects historically attributed to testosterone, including bone mineral density maintenance, suppression of visceral adiposity, lipid profile, and libido. Factorial-design studies have demonstrated that estradiol independently regulates fat accumulation and sexual function in men, and that suppression of estradiol below approximately 20 pg/mL produces metabolic and sexual adverse effects independent of testosterone level.
Empiric aromatase inhibitor (AI) co-prescription with TRT is therefore not recommended. The reflex use of anastrozole 0.5–1 mg twice weekly that proliferated in commercial men's health clinics has no supporting RCT evidence in eugonadal-range estradiol and carries documented risks: reduced bone mineral density, dyslipidemia, arthralgia, and possible cognitive effects.
Indications for anastrozole 0.25–0.5 mg twice weekly are narrow: (1) symptomatic gynecomastia or persistent breast tenderness with estradiol above 50–60 pg/mL on sensitive LC-MS/MS assay; (2) refractory water retention with confirmed elevated estradiol; (3) obese men with baseline aromatase excess in whom weight loss is not feasible. The target is estradiol 20–35 pg/mL, not suppression below 20 pg/mL. Standard immunoassays for estradiol are unreliable in men at low concentrations; LC-MS/MS is preferred.
If gynecomastia is established and tender (typically within the first 6 months of therapy), tamoxifen 10–20 mg daily for 3–6 months is more effective than anastrozole at reversing glandular tissue, with stronger evidence in the breast cancer prevention literature applied off-label here. Once fibrosis develops beyond 12 months, pharmacologic reversal is unlikely and surgical referral is appropriate.
Monitoring on AI therapy should include estradiol at 6 weeks after dose changes, bone densitometry at baseline and every 2 years, and lipid panel annually. AI dosing should be titrated by symptoms and LC-MS/MS estradiol, not empiric schedules. Patients should be counseled that estradiol within 20–35 pg/mL is physiologic and beneficial; the goal is not zero. A useful clinical pearl: men who report worsening joint pain, depressed mood, or low libido after starting an AI are typically over-suppressed, and the AI should be stopped or halved before adjusting testosterone.
Pre-TRT Screening and Contraindications
Before initiating therapy, the following baseline panel should be documented: two morning total testosterone measurements (08:00–10:00, fasting, separated by 1–4 weeks), free testosterone by equilibrium dialysis or calculated from total testosterone, SHBG, and albumin, LH, FSH, prolactin (to exclude pituitary adenoma if LH/FSH are inappropriately normal or low), estradiol by LC-MS/MS, PSA in men over 40, complete blood count with hematocrit, comprehensive metabolic panel, lipid panel, HbA1c, ferritin and iron studies, vitamin D, and TSH.
Absolute contraindications: untreated prostate cancer or breast cancer, severe untreated obstructive sleep apnea, severe lower urinary tract symptoms (IPSS above 19), uncontrolled congestive heart failure (NYHA class IV), recent (within 6 months) myocardial infarction, stroke, or unstable angina, active venous thromboembolism, and male-factor infertility with active conception plans (use hCG or clomiphene instead).
Relative contraindications requiring shared decision-making: baseline hematocrit above 48% (above 50% at high altitude) [PMID 29562364], PSA above 4 ng/mL or rising velocity above 0.75 ng/mL/year without urologic clearance, prior thrombophilia or unprovoked VTE, IPSS 12–19, BPH requiring catheterization, polycythemia vera or other myeloproliferative disorder, history of atrial fibrillation, and age above 80 in the absence of clear symptomatic indication. A digital rectal exam and PSA should be performed at baseline in men over 40, with urology referral for any abnormality before initiation.
Functional secondary hypogonadism in obese men deserves separate emphasis: weight loss raises testosterone in proportion to the weight lost [PMID 23482592] and should precede TRT consideration unless symptoms are severe or testosterone is below 200 ng/dL [PMID 28359097]. Glucagon-like peptide-1 receptor agonists, bariatric surgery, and structured lifestyle interventions all produce measurable testosterone recovery proportional to weight lost.
A pragmatic pre-initiation checklist: confirm two morning testosterone values below age-adjusted thresholds, document at least three classic symptoms (low libido, erectile dysfunction, decreased morning erections, reduced muscle mass, fatigue, depressed mood), exclude reversible causes (medications, opioids, glucocorticoids, hyperprolactinemia, hemochromatosis, hypothyroidism), discuss fertility plans and offer sperm banking if relevant, optimize OSA and obesity, and obtain written informed consent that explicitly addresses cardiovascular risk, erythrocytosis, infertility, and the long-term commitment of therapy. The decision to start TRT is reversible only with a recovery interval; this should be made clear at the first visit, not after suppression has occurred.
